Clinical immunogenicity in rAAV gene therapy: Insights and implications
Molecular Therapy Advances · 2026-12 · 34 (4) · 201848
DOI: 10.1016/j.omta.2026.201848 ↗At a glance
Übersichtsarbeit in Molecular Therapy Advances, 2026-12. Written by Nitish Gulve and 6 co-authors. Institution: Alexion, AstraZeneca Rare Disease, New Haven, CT 06510, USA. Cited 1 times so far (Crossref); 181 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Alexion Pharmaceuticals Inc.
Abstract (original language)
Tiivistelmää ei ole saatavilla.
Subjects
Author keywords
Authors and institutions
- Alexion, AstraZeneca Rare Disease, New Haven, CT 06510, USA.
- Alexion, AstraZeneca Rare Disease, Durham, NC 27701, USA.
- Alexion, AstraZeneca Rare Disease, Wilmington, DE 19803, USA.
- Alexion, AstraZeneca Rare Disease, Boston, MA 02210, USA.
Funding
- Alexion Pharmaceuticals Inc
Cite
APA
Gulve, N., Bego, M., Gandhi, H., Khan, Z., Tong, O., Katebifar, S., & Rajadhyaksha, M. (2026). Clinical immunogenicity in rAAV gene therapy: Insights and implications. Molecular Therapy Advances, 34(4), 201848. https://doi.org/10.1016/j.omta.2026.201848
Vancouver
Gulve N, Bego M, Gandhi H, Khan Z, Tong O, Katebifar S, et al. Clinical immunogenicity in rAAV gene therapy: Insights and implications. Molecular Therapy Advances. 2026;34(4):201848. doi:10.1016/j.omta.2026.201848
BibTeX
@article{Gulve2026,
author = {Gulve, Nitish and Bego, Mariana and Gandhi, Hitesh and Khan, Zilehuma and Tong, Olivia and Katebifar, Sara and Rajadhyaksha, Manoj},
title = {Clinical immunogenicity in rAAV gene therapy: Insights and implications},
journal = {Molecular Therapy Advances},
year = {2026},
volume = {34},
number = {4},
pages = {201848},
doi = {10.1016/j.omta.2026.201848}
}
EUVIMED